Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Invasive Breast Carcinoma|Locally Advanced HER2-Positive Breast Carcinoma|Metastatic HER2-Positive Breast Carcinoma|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8
Interventions: DRUG: Carboplatin|DRUG: Docetaxel|DRUG: Fulvestrant|BIOLOGICAL: Pertuzumab|OTHER: Quality-of-Life Assessment|DRUG: Ribociclib|BIOLOGICAL: Trastuzumab|DRUG: Tucatinib
Sponsor: Jonsson Comprehensive Cancer Center
Collaborators: Seagen Inc.|Novartis